Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.
This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.
All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.
Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in three major upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 2:40 PM CDT, the Jefferies Global Healthcare Conference on June 4 at 3:45 PM EDT, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 10:40 AM EDT. Investors can access live webcasts of all presentations through Bio-Techne's Investor Relations website.
Bio-Techne (NASDAQ: TECH) will showcase its latest innovations at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting in New Orleans from May 13-17. Key highlights include the new RNAscope™ protease-free workflow for AAV vector visualization, ProPak™ GMP cytokines in dose-optimized bags, and the next-generation Simple Western Leo™ System capable of processing 100 samples in 3 hours.
The company will host a symposium on May 14th featuring presentations from industry leaders, including speakers from Dyno Therapeutics and Tessera Therapeutics. An additional talk on protein quantitation applications will be held on May 15th with speakers from Sangamo Therapeutics and Nervosave Therapeutics.
Bio-Techne (NASDAQ: TECH) and Kytopen have announced a partnership to enhance cell therapy manufacturing through integrated cellular engineering workflow. The collaboration combines Bio-Techne's TcBuster™ GMP non-viral genome engineering system with Kytopen's Flowfect Tx™ GMP cellular engineering platform.
The TcBuster™ system enables simultaneous delivery of multiple genes with high editing efficiency in a single vector, while Flowfect® technology processes billions of cells in minutes using a combination of mechanical, electrical, and chemical forces. Together, these technologies aim to streamline gene delivery processes and accelerate the development of advanced cell therapies.
The companies will present their collaborative data at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting in New Orleans, May 7-10, 2025.
Bio-Techne Corporation (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. Investors and interested parties can access a live webcast of the presentation through Bio-Techne's Investor Relations website, specifically on the IR Calendar page.
Bio-Techne (NASDAQ: TECH) has announced two significant shareholder returns initiatives. The company declared a quarterly dividend of $0.08 per share, payable on May 30, 2025, to shareholders of record as of May 19, 2025. Additionally, the Board approved a new $500 million share repurchase program effective May 8, 2025, replacing the previous program.
The timing and volume of share repurchases will be determined by various factors including share price, market conditions, and regulatory requirements. Bio-Techne, a global life sciences company providing research and clinical diagnostic tools, reported $1.2 billion in net sales for fiscal 2024 and employs approximately 3,100 people worldwide.
ScaleReady has awarded a $300,000 G-Rex® Grant to A2 Biotherapeutics to support process development and evaluation of G-Rex for manufacturing cell therapies. The grant enables A2 to explore the G-CART process, a standardized workflow for CAR-T drug product manufacturing, developed by Cell Ready.
A2 will evaluate this platform for their proprietary Tmod™ platform, a dual-signal integrator system for cancer cell therapy targeting various solid tumor indications including colorectal, lung, pancreatic, and ovarian cancers. The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, has been extended with millions in additional funding.
ScaleReady has awarded a $200,000 G-Rex® Grant to March Biosciences to advance the manufacturing of MB-105, a novel CAR-T cell therapy. The therapy targets CD5 for patients with T-cell lymphomas and received FDA orphan drug designation in January 2025.
MB-105 is being developed for multiple CD5-positive blood cancers, including T-cell lymphoma, T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma. The therapy's proprietary design allows it to target malignant cells while preserving normal T-cell function.
The G-Rex Grant Program, which has awarded nearly 200 grants with over 50 new applications pending, provides up to $300,000 per recipient. Grant recipients gain access to ScaleReady's consortium of partners, offering expertise in:
- cGMP manufacturing
- Quality and regulatory affairs
- CGT business operations
The program has been extended with millions in additional funding to continue supporting cell and gene therapy development.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
